Repligen Corporation (RGEN)
Symbol Info
Listed Symbol RGEN
Name Repligen Corporation
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $194,032,000
Latest Fiscal EPS $0.37
Price Info
21 Day Moving Average $90.9567
21 Day EMA $89.976330
50 Day Moving Average $85.7010
50 Day EMA $85.241580
200 Day EMA $69.327130
200 Day Moving Average 66.686000
52 Week High $99.25
52 Week Low $48.26
52 Week Change $89.447900
Alpha 0.025435
Beta 1.1472
Standard Deviation 0.116602
R2 0.116535
Periods 60
Share Information
10 Day Average Volume 547,689
20 Day Average Volume 671,211
30 Day Average Volume 645,866
50 Day Average Volume 616,132
Outstanding Shares 51,530,792
Float Shares 49,006,196
Percent Float 95.10%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 487
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 2,863,372
Institute Holdings Percent -
Institute Sold Previous 3 Months 4,694,795
Insider Holdings Date 2019-07-31
Insider Bought Previous 3 Months 29,912
Insider Holdings Percent 4.90%
Insider Sold Previous 3 Months 10,001
Insiders Shares Owned 2,524,596
Price Change
7 Day Price Change $0.8000031
7 Day Percent Change 0.87%
21 Day Price Change $0.1299973
21 Day Percent Change 0.14%
30 Day Price Change $4.1999970
30 Day Percent Change 4.75%
Month To Date Price Change $-1.75
Month To Date Percent -1.85%
90 Day Price Change $22.690002
90 Day Percent Change 32.44%
Quarter To Date $6.690002
Quarter To Date Percent 7.78%
180 Day Price Change $32.450000
180 Day Percent Change 53.91%
200 Day Price Change $37.670000
200 Day Percent Change 68.53%
Year To Date $39.899998
Year To Date Percent 75.65%
Profile
Description Repligen Corp is a bioprocessing company that develops, produces and commercializes innovative biologic drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in the United States.
Details
Issue Type CS
Market Cap $4,773,812,571
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 51,530,792
CEO Tony J. Hunt
Employees 548
Last Audit UQ
Classification
CIK 0000730272
Industry Biotechnology
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address 41 Seyon Street, Building 1
Suite 100
Waltham, MA 2453
Website https://www.repligen.com
Facisimile +1 781 250-0115
Telephone +1 781 250-0111
Email investors@repligen.com
Key Ratios
Profitability
EBIT Margin 17.40
EBITDA Margin 24.7
Pre-Tax Profit Margin 12.2
Profit Margin Cont 11.42
Gross Margin 55.60
Profit Margin TOT 11.42
Income Statements
Revenue $232,797,000
Revenue Per Share $4.5176
Revenue 3 Years $28.60
Revenue 5 Years $27.71
Valuation Measures
PE Ratio 155.10
Enterprise Value $4,475,634,012
Price To Sales 20.506332
Price To Free Cash -31.9
PE High Last 5 Years 169.9
Price To Book 5.2
Price To Cash Flow 78.6
PE Low Last 5 Years 23.9
Price To Tangible Book 24.1
Financial Strength
Total Debt To Equity 0.2
Int Coverage 5.9
Current Ratio 2.2
Leverage Ratio 1.2
Quick Ratio 1.8
Long Term Debt To Capital 0.02
Assets
Receivables Turnover 2.9
Invoice Turnover 2.20
Assets Turnover 0.10
Management Effectiveness
Return Assets 2.93
Return On Equity 3.60
Return On Capital 3.70
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
RGEN
Repligen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.